Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians

Genetic Testing and Molecular Biomarkers

Volumn 14, Issue 3, 2010, Pages 329-342

  Gra, Olga ^a,b   Mityaeva, Olga ^a   Berdichevets, Iryna ^b   Kozhekbaeva, Zhanna ^c   Fesenko, Denis ^a   Kurbatova, Olga ^b   Goldenkova Pavlova, Irina ^b   Nasedkina, Tatyana ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 2; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HLA DQA1 ANTIGEN; METHIONINE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 1; UNCLASSIFIED DRUG; BLOOD GROUP ABO SYSTEM; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; HLA DQ ANTIGEN; HLA-DQA1 ANTIGEN; METHIONINE SYNTHASE REDUCTASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIXED FUNCTION OXIDASE; NAT2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNSPECIFIC MONOOXYGENASE; XENOBIOTIC AGENT;

ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; DNA POLYMORPHISM; EUROPE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HISTOCOMPATIBILITY GENE; HUMAN; INDIGENOUS PEOPLE; LEUKEMIA; LYMPHOMA; MALE; MICROARRAY ANALYSIS; MICROCHIP ANALYSIS; MULTIPLEX POLYMERASE CHAIN REACTION; NORMAL HUMAN; POPULATION GENETICS; RUSSIAN FEDERATION; TUBERCULOSIS; ADOLESCENT; CAUCASIAN; DNA MICROARRAY; EPIDEMIOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PROCEDURES; YOUNG ADULT;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FERREDOXIN-NADP REDUCTASE; GENE FREQUENCY; GENETICS, POPULATION; GLUTATHIONE TRANSFERASE; HLA-DQ ALPHA-CHAINS; HLA-DQ ANTIGENS; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIXED FUNCTION OXYGENASES; NAD(P)H DEHYDROGENASE (QUINONE); OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOREDUCTASES; POLYMORPHISM, GENETIC; RUSSIA; XENOBIOTICS; YOUNG ADULT;

EID: 77954890041     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2009.0158     Document Type: Article

References (95)

1. Artamonov VV, Lyubchenko LN, Shabanov MA, et al. (2004) The association of NAT2 polymorphisms with sporadic breast cancer. Mol Biol (Mosk) 38:457-462.
2. Bartsch H, Nair U, Risch A, et al. (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomark Prev 9: 3-28.
3. Boduroglu K, Alanay Y, Alikasifoglu M, et al. (2005) Analysis of MTHFR 1298A>C in addition to MTHFR 677C>T polymorphism as a risk factor for neural tube defects in the Turkish population. Turk J Pediatr 47:327-333.
4. Bonner MR, Bennett WP, Xiong W, et al. (2006) Radon, secondhand smoke, glutathione-S-transferase M1 and lung cancer among women. Int J Cancer 119:1462-1467.
5. Botto LD, Young Q (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151:862-877.
6. Botto N, Andreassi MG, Manfredi S, et al. (2003) Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Hum Genet 11:671-678.
7. Bozina N, Granić P, Lalić Z, et al. (2003) Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 44:425-428.
8. Brockton N, Little J, Sharp L, et al. (2000) N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 151:846-861.
9. Casas JP, Hingorani AD, Bautista LE, et al. (2004) Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 61:1652-1661.
10. Chao C, Zhang ZF, Berthiller J, et al. (2006) NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:979-987.
11. Cinek O, Kolousková S, Snajderová M, et al. (2001) HLA class II genetic association of type 1 diabetes mellitus in Czech children. Pediatr Diabetes 2:98-102.
12. Crnić-Martinović M, Grahovac B, Jeras BV, et al. (2007) HLA class II polymorphism in autochthonous population of Gorski kotar, Croatia. Coll Antropol 31:853-858.
13. D'Alo F, Voso MT, Guidi F, et al. (2004) Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica 89:664-670.
14. Deakin M, Elder J, Hendrickse C, et al. (1996) Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 17:881-884.
15. Dean JC, Robertson Z, Reid V, et al. (2008) A high frequency of the MTHFR 677C>T polymorphism in Scottish women with epilepsy: possible role in pathogenesis. Seizure 17:269-275.
16. Deitz AC, Rothman N, Rebbeck TR, et al. (2004) Impact of mis-classification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 13:1543-1546.
17. Eguchi-Ishimae M, Eguchi M, Ishii E, et al. (2005) The association of a distinctive allele of NAD(P)H:quinone oxidoreductase with pediatric acute lymphoblastic leukemias with MLL fusion genes in Japan. Haematologica 90:1511-1515.
18. Elexpuru-Camiruaga J, Buxton N, Kandula V, et al. (1995) Susceptibility to astrocytoma and meningioma: influence of al-lelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res 55:4237-4239.
19. Engel LS, Taioli E, Pfeiffer R, et al. (2002) Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 156:95-109.
20. Erlich H, Valdes AM, Noble J, et al. (2008) HLA DR-DQ haplo-types and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57: 1084-1092.
21. Eskes TK (2006) Abnormal folate metabolism in mothers with Down syndrome offspring: review of the literature. Eur J Obstet Gynecol Reprod Biol 124:130-133.
22. Fagerholm R, Hofstetter B, Tommiska J, et al. (2008) NAD(P)H: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844-853.
23. Fux R, Morike K, Prohmer AM, et al. (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78:378-387.
24. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59:303-312.
25. Gallegos-Arreola MP, Gomez-Meda BC, Morgan-Villela G, et al. (2003) GSTT1 gene deletion is associated with lung cancer in Mexican patients. Dis Markers 19:259-261.
26. Gardiner SG, BeggEJ(2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Clin Pract Pharmacol Rev 58: 521-590.
27. Garte S, Gaspari L, Alexandrie AK, et al. (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239-1248.
28. Gemignani F, Landi S, Szeszenia-Dabrowska N, et al. (2007) Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 28:1287-1293.
29. Ghodke Y, Joshi K, Chopra A, et al. (2005) HLA and disease. Eur J Epidemiol 20:475-488.
30. Glotov AS, Nasedkina TV, Ivashchenko TE, et al. (2005) Biochip development for polymorphism analysis in biotransformation system genes. Mol Biol (Mosk) 39:403-412.
31. Goldenkova-Pavlova IV, Bruskin SA, Abdeev RM, et al. (2006) Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping. Genet-ika 42:1143-1150.
32. Gonzalez HM, Romero EM, Peregrina AL, et al. (2003) CYP2C19-and CYP3A4-dependent omeprazole metabolism in west Mexicans. J Clin Pharmacol 43:1211-1215.
33. Gra OA, Glotov AS, Nikitin EA, et al. (2008) Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lym-phocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol 83:279-287.
34. Gra OA, Glotov AS, Kozhekbaeva ZhM, et al. (2008a) Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia. Mol Biol (Mosk) 42:214-225
35. Gra OA, Kozhekbaeva ZhM, Makarova OV, et al. (2009) Polymorphism of biotransformation genes and risk of relapse in childhood acute leukemia. Balkan J Med Genet 12:21-35.
36. Guéant-Rodriguez RM, Juilliére Y, Candito M, et al. (2005) Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homo-cysteine and coronary artery disease in the French population. Thromb Haemostasis 94:510-515.
37. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
38. Gulyaeva LF, Mikhailova ON, PustyInyak VO, et al. (2008) Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 617:359-366.
39. Hamdy SI, Hiratsuka M, Narahara K, et al. (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehy-drogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596-603.
40. Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogene-sis. Mutat Res 506:65-77.
41. Hein DW, Doll MA, Fretland AJ, Leff MA, et al. (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acety-lation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42.
42. Hernández A, Xamena N, Surrallés J, et al. (2008) Role of GST and NAT2 polymorphisms in thyroid cancer. J Endocrinol Invest 31:1025-1031.
43. Hirata H, Hinoda Y, Okayama N, et al. (2008) CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112:1964-1973.
44. Hirvonen A (1999) Polymorphic NATs and cancer predisposition. IARC Sci Publ 148:251-270.
45. Hobbs CA, Cleves MA, Lauer RM, et al. (2002) Preferential transmission of the MTHFR 677 T allele to infants with Down syndrome: implications for a survival advantage. Am J Med Genet 113:9-14.
46. Hobbs CA, Sherman SL, Yi P, et al. (2000) Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 67:623-630.
47. Hohaus S, Massini G, D'Alo F, et al. (2003) Association between glutathione S-transferase genotypes and Hodgkin's lym-phoma risk and prognosis. Clin Cancer Res 9:3435-3540.
48. Jones EY, Fugger L, Strominger JL, et al. (2006) MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 6:271-282.
49. Kang SH, Kim TY, Kim HY, et al. (2006) Association of NQO1 polymorphism with multiple myeloma risk in Koreans. Korean J Lab Med 26:71-76.
50. Kara I, Sazci A, Ergul E, et al. (2003) Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahy-drofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res 111:84-90.
51. Kerridge I, Lincz L, Scorgie F, et al. (2002) Association between xenobiotic gene polymorphisms and non-Hodgkin's lym-phoma risk. Br J Haematol 118:477-481.
52. Khrunin AV, Khokhrin DV, Limborskaia SA (2008) Glutathione-S-transferase gene polymorphism in Russian populations of European Russia. Genetika 44:1429-1434.
53. Kim HN, Kim YK, Lee IK, et al. (2009) Association between polymorphisms of folate-metabolizing enzymes and hemato-logical malignancies. Leuk Res 33:82-87.
54. Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44: 1083-1105.
55. Kirchheiner J, Brockmoller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1-16.
56. Kozhekbaeva ZhM, Glotov AS, Gra OA, et al. (2007) Identification of functionally significant mutations in NAT2 gene using biological microchips. Mol Biol (Mosk) 41:725-733.
57. Kozhekbaeva ZhM, Gra OA, Fadeev VS, et al. (2009) Association of NAT2 polymorphisms with susceptibility to psoriasis in the Moscow population. Mol Biol (Mosk) 43:22-67.
58. Laivoranta-Nyman S, Möttönen T, Hermann R, et al. (2004) HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis. Ann Rheum Dis 63:1406-1412.
59. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12:251-263.
60. Li D, Ahmed M, Li Y, et al. (2005) 5,10-Methylenetetrahy-drofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14:1470-1476.
61. Lie BA, Thorsby E (2005) Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr Opin Immunol 17:526-531.
62. Mizutani T (2003) PM Frequencies of Major CYPs in Asians and Caucasians. Drug Metab Rev 35:99-106.
63. Monsuur AJ, de Bakker PI, Zhernakova A, et al. (2008) Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphisms. PLoS ONE 3:e2270.
64. Morari EC, Pereira Leite JL, Granja F, et al. (2002) The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol Bio-markers Prev 11:1485-1488.
65. Moulds JM, Moulds JJ (2000) Blood group associations with parasites, bacteria, and viruses. Transfusion Med Rev 14: 302-311.
66. Muntjewerff JW, Kahn RS, Blom HJ, et al. (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11:143-149.
67. Nasedkina TV, Fesenko DO, Mityaeva ON, et al. (2008) Determination of phenotypic characteristics of an individual on the basis of analysis of genetic markers using biological microchips. Dokl Biochem Biophys 422:304-307.
68. Nasedkina TV, Gra OA, Kozhekbaeva ZhM, et al. (2008a) Metabolizing gene polymorphism analysis and susceptibility to lymphoproliferative diseases in Russian population. In: Koven TV (ed) Population Genetics Research Progress. Nova Science Publishers Inc., New York, pp 245-277.
69. Naushad SM, Jain Jamal MN, Prasad CK, et al. (2008) Relationship between methionine synthase, methionine synthase re-ductase genetic polymorphisms and deep vein thrombosis among South Indians. Clin Chem Lab Med 46:73-79.
70. Nebert DW, Roe AL, Vandale SE, et al. (2002) NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease:a HuGE review. Genet Med 4:62-70.
71. Oliveira E, Marsh S, van Booven DJ, et al. (2007) Pharmacogen-etically relevant polymorphisms in Portugal. Pharmacoge-nomics 8:703-712.
72. Rady PL, Szucs S, Grady J, et al. (2002) Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methi-onine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 107:162-168.
73. Resic-Lindehammer S, Larsson K, Ortqvist E, et al. (2008) Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk. Acta Diabetol 45:231-235.
74. Rubina AY, Pan'kov SV, Dementieva EI, et al. (2004) Hydro-gel drop microchips with immobilized DNA: properties and methods for large-scale production. Anal Biochem 325: 92-106.
75. Sachse C, Smith G, Wilkie MJ, et al. (2002) A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23:1839-1849.
76. Sanderson S, Salanti G, Higgins J (2007) Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol 166:741-751.
77. Schmidt H, Williamson D, Ashley-Koch A (2007) HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 165:1097-10109.
78. Sekine I, Saijo N (2001) Polymorphism of metabolizing enzymes and transporter proteins involved in the clearance of anti-cancer agents. Ann Oncol 12:1515-1525.
79. Sharma A, Mishra A, Das BC, et al. (2006) Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. Neoplasma 53:309-315.
80. Smith GB, Harper PA, Wong JM, et al. (2001) Human lung mi-crosomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione s-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 10:839-853.
81. Song CY, Xing DY, Tan W, et al. (2001) Methylenetetrahy-drofolate reductase polymorphisms increase risk of esopha-geal squamous cell carcinoma in a Chinese population. Cancer Res 61:3272-3275.
82. Stanevicha V, Eglite J, Zavadska D, et al. (2007) HLA class II DR and DQ genotypes and haplotypes associated with rheumatic fever among a clinically homogeneous patient population of Latvian children. Arthritis Res Ther 9:R58.
83. Strange RC, Spiteri MA, Ramachandran S, et al. (2001) Glu-tathione S-transferase family of enzymes. Mut Res 482:21-26.
84. Van der Hel OL, Bueno-de-Mesquita HB, van Gils CH, et al. (2005) Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands). Cancer Causes Control 16:675-681.
85. Van der Put NM, Gabreels F, Stevens EM, et al. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62:1044-1051.
86. Vogl FD, Taioli E, Maugard C, et al. (2004) Glutathione S-transferases M1, T1, and P1 and breast cancer. A pooled analysis. Cancer Epidemiol Biomarkers Prev 13:1473-1479.
87. Wang SS, Qiao FY, Feng L, et al. (2008) Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. J Zhejiang Univ Sci B 9:93-99.
88. Wenzlaff AS, Cote ML, Bock CH, et al. (2005) GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26:395-401.
89. Wiemels JL, Smith RN, Taylor GM, et al. (2001) Methylenete-trahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 98:4004-4009.
90. Wilcken B, Bamforth F, Li Z, et al. (2003) Geographical and ethnic variation of the 677C>T allele of 5,10 methylenete-trahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 40: 619-625.
91. Wu MS, Shun CT, Huang SP, et al. (2004) Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lym-phoma. Haematologica 89:1015-1017.
92. Wu O, Bayoumi N, Vickers MA, et al. (2008) ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemostasis 6:62-69.
93. Zhang FF, Terry MB, Hou L, et al. (2007) Genetic polymorphisms in folate metabolism and the risk of stomach cancer. Cancer Epidemiol Biomarkers Prev 16:115-121.
94. Zhang J, Schulz WA, Li Y, et al. (2003) Association of NAD(P)H: quinine oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 24: 905-909.
95. Zhang X, Wei S, Yang S, et al. (2004) HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han. Int J Dermatol 43:181-187.